Clinical Trial Update: Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update covers Roche's Phase 1/2 study of mosunetuzumab as consolidation after first-line immunochemotherapy and as monotherapy or with polat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• LUNSUMIO (mosunetuzumab)
• Polivy (polatuzumab vedotin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Diffuse Large B-cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED